EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug
Novo Nordisk has received approval for the oral version of its Wegovy weight loss drug in the European Union. This follows the U.S. approval of the pill form in December, which has seen a surge in prescriptions. The Wegovy pill will be available only to adults, while the injectable version can be prescribed to patients aged 12 and older.
- ▪The European Medicines Agency has recommended an extension to the marketing authorization for Wegovy to include an oral formulation.
- ▪Novo Nordisk expects to start selling the pill in other markets in the second quarter of this year.
- ▪Pricing for the Wegovy pill will be determined by EU member states.
Korea Times publishes from South Korea and files mainly under world. We currently carry 375 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Korea Times |
| Canonical URL | https://www.koreatimes.co.kr/world/20260522/eu-regulator-approves-pill-form-of-novo-nordisks-wegovy-weight-loss-drug?utm_source=rss |
| Publication time | Fri, 22 May 2026 13:07:02 GMT |
| Retrieval time | 2026-05-22T13:12:02.303Z |
| Last seen | 2026-05-22T13:12:02.303Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | PlToa7-0rN07 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Reuters-YonhapCOPENHAGEN — Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc's medicines regulator said on Friday.The European Medicines Agency said it had "recommended an extension to the marketing authorization for Wegovy (semaglutide) in the EU to add an oral formulation for weight management", alongside the injectable treatment.The decision follows U.S.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Korea Times.
Discussion
0 commentsMore from Korea Times
